OOIR: Observatory of International Research

Papers

(The H4-Index of CNS Drugs is 32. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond	114
Post-COVID-19 Depressive Symptoms: Epidemiology, Pathophysiology, and Pharmacological Treatment	91
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies	89
Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications	85
Overview of Current Drug Delivery Methods Across the Blood–Brain Barrier for the Treatment of Primary Brain Tumors	75
Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination	75
Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies	75
Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status	71
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview	69
Intranasal Insulin for Alzheimer’s Disease	68
Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox–Gastaut Syndrome	50
Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression	49
Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis	49
Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analys	47
Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies	47
The Cardiovascular Effects of Newer Antidepressants in Older Adults and Those With or At High Risk for Cardiovascular Diseases	45
Adjunctive Cenobamate for Focal-Onset Seizures in Adults: A Systematic Review and Meta-Analysis	43
A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia	43
Siponimod: A Review in Secondary Progressive Multiple Sclerosis	41
Pharmacological Treatments for Borderline Personality Disorder: A Systematic Review and Meta-Analysis	39
A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication	39
Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study	38
Pharmacology of Cenobamate: Mechanism of Action, Pharmacokinetics, Drug–Drug Interactions and Tolerability	38
Expanding the Treatment Landscape for Lennox-Gastaut Syndrome: Current and Future Strategies	38
Cannabis-Based Medicines and Medical Cannabis for Chronic Neuropathic Pain	37

Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score	36
Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders	36
Methadone for Pain Management: A Pharmacotherapeutic Review	35
Benzodiazepines in the Management of Seizures and Status Epilepticus: A Review of Routes of Delivery, Pharmacokinetics, Efficacy, and Tolerability	34
Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status	32
Efficacy and Safety of HSK3486 for Anesthesia/Sedation in Patients Undergoing Fiberoptic Bronchoscopy: A Multicenter, Double-Blind, Propofol-Controlled, Randomized, Phase 3 Study	32
Fenfluramine for the Treatment of Dravet Syndrome and Lennox–Gastaut Syndrome	32
Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia	32